Actavis files opposition to motion for preliminary injunction in Nameda antitrust litigation
MLex Summary: Actavis and its subsidiary Forest Laboratories filed an opposition to New York's motion for preliminary injunction against the drugmakers over the Alzheimer's drug Nameda. The opposition argues that there is...To view the full article, register now.
Already a subscriber? Click here to view full article